I N S E R M INST NAT DE LA SAN has a total of 12 patent applications. Its first patent ever was published in 1999. It filed its patents most often in EPO (European Patent Office), Canada and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are LICENTIA LTD, LUDWIG INST CANCER RES and SAHIN UGUR.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | Canada | 2 | |
#3 | WIPO (World Intellectual Property Organization) | 2 | |
#4 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Gregoire Marc | 2 |
#2 | Bartholeyns Jacques | 2 |
#3 | Benessiano Joelle | 2 |
#4 | Steg Philippe Gabriel | 2 |
#5 | Tedgui Alain | 2 |
#6 | Freyssinet Jean-Marie | 2 |
#7 | Mallat Ziad | 2 |
#8 | Aunis Dominique | 1 |
#9 | Faivre-Chauvet Alain | 1 |
#10 | Diarra-Mehrpour Maryam | 1 |
Publication | Filing date | Title |
---|---|---|
EP1987839A1 | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease | |
EP1739092A1 | Peptidic antagonists of class III semaphorins/neuropilins complexes | |
EP1739455A1 | Chirp reversal ultrasound contrast imaging | |
EP1714153A2 | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual | |
EP1392820A1 | Cyp450-specific dna probes and primers, and biological applications thereof | |
WO0105946A1 | Model for studying the evolution of spontaneous pulmonary metastases, and use for screening medicines |